Slowed Gompertzian ageing in long-lived C. elegans results from expansion of decrepitude, not decelerated ageing

Key findings from this study

This research indicates that:

• Reductions in the Gompertz β parameter during lifespan extension stem from expanded decrepitude rather than slowed biological ageing
• Reductions in the Gompertz α parameter correlate with healthspan expansion and more accurately reflect decelerated biological ageing
• The traditional interpretation of Gompertz parameters inverts their actual biological meaning in the context of life-extending interventions

Overview

Mortality rates in animal populations typically follow the Gompertz equation, characterized by two parameters: α (mortality scale) and β (rate of increase with age). The study investigates whether reductions in these parameters during lifespan extension reflect biological slowing of ageing or other mechanisms. Using C. elegans populations and individual-level analysis, the research reinterprets traditional understandings of what α and β represent biologically.

Methods and approach

The investigators combined population-level mortality studies with individual-level assessments of health changes in C. elegans. They applied life-extending interventions and measured effects on both Gompertz parameters and healthspan measures. Population mortality trajectories were analyzed alongside age-related physiological changes in longer-lived animals.

Results

Reductions in β during lifespan extension do not result from decelerated biological ageing. Instead, longer-lived animals exhibited expanded decrepitude (gerospan), the period of physiological decline. Parameter α demonstrated stronger correspondence with healthspan expansion, which the authors identify as an indicator of slowed biological ageing. These findings contradict the conventional interpretation that β represents ageing rate while α captures age-independent mortality.

Implications

The revised understanding of Gompertz parameters has substantial implications for gerontological research. Interventions classified as slowing ageing based on β reduction may instead extend the duration of age-related decline without altering underlying biological rates. Future lifespan studies require direct assessment of healthspan and decrepitude duration to distinguish genuine ageing deceleration from gerospan expansion.

This reinterpretation affects how researchers evaluate candidate anti-ageing therapies. Reliance on Gompertz parameter changes alone provides incomplete mechanistic insight. The work emphasizes the necessity of integrating population-level mortality analysis with individual-level health trajectories to characterize ageing biology accurately.

Scope and limitations

This summary is based on the study abstract and available metadata. It does not include a full analysis of the complete paper, supplementary materials, or underlying datasets unless explicitly stated. Findings should be interpreted in the context of the original publication.